Login to Your Account



Six-Minute Walk Test Debated

Biomarin’s Vimizim: FDA Panel Says Yes to Morquio A Therapy

By Randy Osborne
Staff Writer

Wednesday, November 20, 2013
As expected, Biomarin Pharmaceutical Inc.’s Vimizim (elosulfase alfa), an enzyme replacement therapy for mucopolysaccharidosis (MPS) Type IVA, also called Morquio A syndrome, sailed through an FDA advisory panel with positive voting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription